GBI Research has released the
pharma report, "ADHD Therapeutics to 2020 - Broadened Diagnostic Criteria
and Growing Adult Prevalence to Drive Market Growth despite Patent
Expirations" Changes in diagnostic criteria have reduced the symptom threshold
for diagnosis and finally bring the acceptance of adult ADHD to the clinical
setting, enabling those previously unable to obtain a diagnosis to be diagnosed
for ADHD treatment. In the case of adult ADHD, 4.1% of US adults are believed
to suffer from ADHD, 41.3% of these cases are classified as severe and would be
eligible for therapeutic intervention.
Browse
Full Report With TOC @ http://www.radiantinsights.com/research/adhd-therapeutics-to-2020-broadened-diagnostic-criteria-and-growing-adult-prevalence-to-drive-market-growth-despite-patent-expirations
The current ADHD therapeutics
market is flooded with generics and dominated by the use of Extended-Release
(ER) stimulant drugs which have superseded short-acting, Immediate-Release (IR)
formulations. With dose titration per patient, ER stimulants are usually
effective in 70-90% of patients. However, all stimulants apart from Vyvanse
come with potential for abuse. Non-stimulants are used for those who are
poor-responders, have poor cardiac history or prefer non-stimulant medication
however their efficacy is lacking in comparison. Currently, 10% of adult
patients are using a combination of ER and IR treatment for an additional
duration, representing an unmet need within this growing ADHD segment.
The
current developmental pipeline addresses these gaps in the market, with three
potential non-stimulants entering the market during the forecast period and
SHP465, which aims to address the unmet need in the adult ADHD segment with its
tailored duration of action. In spite of anticipated drug approvals, patents
expirations and increased generic competition will cause ACoT to remain fairly
static and even decrease across some nations.
About Radiant
Insights
Radiant
Insights is a platform for companies looking to meet their market research and
business intelligence requirements. We assist and facilitate organizations and
individuals procure market research reports, helping them in the decision
making process. We have a comprehensive collection of reports, covering over 40
key industries and a host of micro markets. In addition to over extensive
database of reports, our experienced research coordinators also offer a host of
ancillary services such as, research partnerships/ tie-ups and customized
research solutions.
For More
Information, Visit Radiant
Insights
Contact:
Michelle
Thoras
Corporate
Sales Specialist, USA
Radiant
Insights, Inc
Phone:
1-415-349-0054
Toll
Free: 1-888-202-9519
Email:
sales@radiantinsights.com
No comments:
Post a Comment